Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies

被引：0
|
作者：
Mohammad Amin Karimi [1 ]
Hanieh Norooziseyedhosseini [2 ]
Reza Khademi [3 ]
Alireza Ghajary [4 ]
Haniyeh Kargar [5 ]
Seyyedeh Sana Abdollahi [6 ]
Mohaddeseh Belbasi [7 ]
Mahdyieh Naziri [8 ]
Niloofar Deravi [1 ]
Sajjad Hajihosseini [9 ]
Saharnaz Mofidi [9 ]
机构：
[1] Shahid Beheshti University of Medical Sciences,School of Medicine
[2] I.M. Sechenov First Moscow State Medical University,Student Research Committee, Faculty of Medicine
[3] Mashhad University of Medical Sciences,School of Pharmacy
[4] Mashhad University of Medical Sciences,Faculty of Medicine
[5] Islamic Azad University,Student Research Committee, Faculty of Pharmacy
[6] Tabriz University of Medical Sciences,Students Research Committee, School of Pharmacy
[7] Zanjan University of Medical Sciences,Students Research Committee, School of Medicine
[8] Iran University of Medical Sciences,undefined
[9] Student Research Committee,undefined
[10] Tehran University of Medical Sciences,undefined
来源：
BMC Pharmacology and Toxicology | / 26卷 / 1期
关键词：
Ibrutinib; Refractory CLL; Chronic lymphocyte leukemia; Relapsed CLL; Meta-analysis;
D O I：
10.1186/s40360-024-00832-9
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    BLOOD, 2021, 137 (08) : 1117 - 1120
  • [2] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Brown, J. R.
    Eichhorst, B.
    Hillmen, P.
    Jurczak, W.
    Kazmierczak, M.
    Lamanna, N.
    O'Brien, S. M.
    Tam, C. S.
    Qiu, L.
    Zhou, K.
    Simkovic, M.
    Mayer, J.
    Gillespie-Twardy, A.
    Ferrajoli, A.
    Ganly, P. S.
    Weinkove, R.
    Grosicki, S.
    Mital, A.
    Robak, T.
    Osterborg, A.
    Yimer, H. A.
    Salmi, T.
    Wang, M. -D. -Y.
    Fu, L.
    Li, J.
    Wu, K.
    Cohen, A.
    Shadman, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04): : 319 - 332
  • [3] IBRUTINIB IN THE MANAGEMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A REAL-LIFE MONOCENTRIC EXPERIENCE
    Albi, E.
    Del Papa, B.
    Dorillo, E.
    Aureli, P.
    Cantelmi, M. G.
    Zei, T.
    Ostini, R. Iacucci
    Ciurnelli, R.
    Falzetti, F.
    Sportoletti, P.
    HAEMATOLOGICA, 2017, 102 : 123 - 123
  • [4] Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
    UK CLL Forum
    HAEMATOLOGICA, 2016, 101 (12) : 1563 - 1572
  • [5] Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)
    Spacek, Martin
    Smolej, Lukas
    Simkovic, Martin
    Nekvindova, Lucie
    Kristkova, Zlatuse
    Brychtova, Yvona
    Panovska, Anna
    Maslejova, Stanislava
    Bezdekova, Lucie
    Ecsiova, Dominika
    Vodarek, Pavel
    Zuchnicka, Jana
    Mihalyova, Jana
    Urbanova, Renata
    Turcsanyi, Peter
    Lysak, Daniel
    Novak, Jan
    Brejcha, Martin
    Likarova, Tereza
    Vodicka, Prokop
    Baranova, Jana
    Trneny, Marek
    Doubek, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (01) : 40 - 47
  • [6] Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
    Hansson, Lotta
    Winqvist, Maria
    Asklid, Anna
    Andersson, P-O
    Karlsson, Karin
    Karlsson, Claes
    Lauri, Birgitta
    Lundin, Jeanette
    Mattsson, Mattias
    Norin, Stefan
    Sandstedt, Anna
    Osterborg, Anders
    BLOOD, 2015, 126 (23)
  • [7] Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis
    Nuttall, Elisabeth
    Tung, Joanna
    Trounce, Ellie
    Johnston, Rosalynd
    Chevassut, Timothy
    JOURNAL OF BLOOD MEDICINE, 2019, 10 : 199 - 208
  • [8] Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kim, Haesook T.
    Savell, Alexandra
    Santiago-Medero, Carlos
    Francoeur, Karen
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2017, 130
  • [9] Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia
    Monica, Magdalena
    Reczek, Monika
    Kawalec, Pawel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [10] Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
    Winqvist, Maria
    Asklid, Anna
    Andersson, P. O.
    Karlsson, Karin
    Karlsson, Claes
    Lauri, Birgitta
    Lundin, Jeanette
    Mattsson, Mattias
    Norin, Stefan
    Sandstedt, Anna
    Hansson, Lotta
    Osterborg, Anders
    HAEMATOLOGICA, 2016, 101 (12) : 1573 - 1580
12345